LLY · News · 20260923N

Revenue Performance and Mix

ELI LILLY & Co · 2026-09-23 · Importance 64 · Surprise 56 · In source text

Eli Lilly reported a 47.7% increase in Q2 2026 revenue. The reported growth was associated with high demand for GLP-1 medicines. Foundayo and broader GLP-1 production capacity were identified as key commercial priorities supporting future product availability.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
revenuepositiverealized—Eli Lilly reported a strong Q2 2026 revenue increase of 47.7%.